# Section 1: Company Overview

## S1.1: Basic Information

| Field | Value |
| :---- | :---- |
| Company Name | Humana Inc. |
| Establishment Date | January 1, 1964 |
| Headquarters Location | Louisville, United States |


## S1.2 : Core Competencies

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Innovation Advantages | The CenterWell segment includes pharmacy solutions, primary care, and home solutions operations, which are designed to enhance the overall healthcare experience and may lead to lower utilization associated with improved member health and/or lower drug costs. The company is focused on accelerating clinical innovation and developing a value-based operating model at scale. | The CenterWell segment includes pharmacy solutions, primary care, and home solutions operations, which are designed to enhance the overall healthcare experience and may lead to lower utilization associated with improved member health and/or lower drug costs. The company has also fully integrated its home health operations under the CenterWell brand, allowing for the development of a value-based operating model at scale. |
| Product Advantages | The Insurance segment offers a range of Medicare products, including Individual Medicare Advantage, Group Medicare Advantage, and Medicare stand-alone PDP, which collectively represent a significant portion of the company's revenue. The CenterWell segment's integrated care delivery model aims to provide quality care that is consistent, integrated, cost-effective, and member-focused. | Humana's Insurance segment offers a range of products including Medicare Advantage plans, Medicare stand-alone prescription drug plans (PDPs), and specialty benefits such as dental and vision insurance. The company has a significant focus on Medicare products, with 84% of total premiums and services revenue derived from contracts with the federal government. |
| Brand Recognition | Humana's Medicare Advantage plans have historically been recognized for their quality, with a significant percentage of members enrolled in plans rated 4-star or higher. The company has established long-term relationships with various stakeholders, including strategic partnerships with Welsh, Carson, Anderson & Stowe to develop and operate senior-focused primary care centers. | Humana is recognized for its integrated care delivery model, which combines quality care, high member engagement, and sophisticated data analytics. The company has established strategic partnerships, such as with Welsh, Carson, Anderson & Stowe, to expand its primary care model, enhancing its brand presence in the healthcare market. |
| Reputation Ratings | Humana has achieved and maintained NCQA health plan accreditation in many of its Medicare and Medicaid markets, reflecting its commitment to quality improvement and member satisfaction. The company also adheres to various regulatory requirements and standards, including those set by CMS. | Humana maintains accreditation from the National Committee for Quality Assurance (NCQA) for many of its commercial, Medicare, and Medicaid markets, which reflects its commitment to quality improvement and member satisfaction. |


## S1.3 : Mission & Vision

| Field | Value |
| :---- | :---- |
| Mission Statement | We are committed to putting health first - for our teammates, our customers, and our company. |
| Vision Statement | Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health - delivering the care and service they need, when they need it. |
| Core Values | N/A |


# Section 2: Financial Performance

## S2.1: Income Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Revenue | 117,761.0 | 106,374.0 | 92,870.0 | Millions | USD |
| Cost of Goods Sold | 100,664.0 | 88,394.0 | 75,690.0 | Millions | USD |
| Gross Profit | N/A | N/A | N/A | Millions | USD |
| Operating Expense | 115,199.0 | 102,361.0 | 89,070.0 | Millions | USD |
| Operating Income | 2,562.0 | 4,013.0 | 3,800.0 | Millions | USD |
| Net Profit | 1,214.0 | 2,484.0 | 2,802.0 | Millions | USD |
| Income before income taxes | 1,721.0 | 3,383.0 | 3,568.0 | Millions | USD |
| Income tax expense(benefit) | 413.0 | 836.0 | 762.0 | Millions | USD |
| Interest Expense | 660.0 | 493.0 | 401.0 | Millions | USD |


## S2.2: Balance Sheet

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Total Assets | 46,479.0 | 47,065.0 | 43,055.0 | Millions | USD |
| Current Assets | 29,815.0 | 29,986.0 | 26,183.0 | Millions | USD |
| Non-Current Assets | 16,664.0 | 17,079.0 | 16,872.0 | Millions | USD |
| Total Liabilities | 30,034.0 | 30,747.0 | 27,685.0 | Millions | USD |
| Current Liabilities | 16,939.0 | 18,872.0 | 17,178.0 | Millions | USD |
| Non-Current Liabilities | 13,095.0 | 11,875.0 | 10,507.0 | Millions | USD |
| Shareholders' Equity | 16,375.0 | 16,262.0 | 15,311.0 | Millions | USD |
| Retained Earnings | 28,317.0 | 27,540.0 | 25,492.0 | Millions | USD |
| Total Equity and Liabilities | 46,479.0 | 47,065.0 | 43,055.0 | Millions | USD |
| Inventories | N/A | N/A | N/A | Millions | USD |
| Prepaid Expenses | N/A | N/A | N/A | Millions | USD |


## S2.3: Cash Flow Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Net Cash Flow from Operations | 2,966.0 | 3,981.0 | 4,587.0 | Millions | USD |
| Net Cash Flow from Investing | (2,952.0) | (3,492.0) | (1,006.0) | Millions | USD |
| Net Cash Flow from Financing | (2,487.0) | (856.0) | (1,914.0) | Millions | USD |
| Net Increase/Decrease in Cash | (2,473.0) | (367.0) | 1,667.0 | Millions | USD |
| Dividends | (431.0) | (431.0) | (392.0) | Millions | USD |


## S2.4: Key Financial Metrics

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Gross Margin | 14.52% | 16.90% | 18.50% | Millions | USD |
| Operating Margin | 2.18% | 3.77% | 4.09% | Millions | USD |
| Net Profit Margin | 1.03% | 2.34% | 3.02% | Millions | USD |
| Current Ratio | 176.01% | 158.89% | 152.42% | Millions | USD |
| Quick Ratio | N/A | N/A | N/A | Millions | USD |
| Interest Coverage | 388.18% | 814.00% | 947.63% | Millions | USD |
| Asset Turnover | 251.78% | 236.07% | N/A | Millions | USD |
| Debt-to-Equity | 183.41% | 189.07% | 180.82% | Millions | USD |
| Return on Equity | 7.44% | 15.73% | N/A | Millions | USD |
| Return on Assets | 2.60% | 5.51% | N/A | Millions | USD |
| Effective Tax Rate | 24.00% | 24.71% | 21.36% | Millions | USD |
| Dividend Payout Ratio | 35.50% | 17.35% | 13.99% | Millions | USD |

## S2.5: Operating Performance

| Field | 2024 | 2023 | 2022 |
| :---- | :---- | :---- | :---- |
| Revenue by Product/Service | Individual Medicare Advantage: $ 88,019, Group Medicare Advantage: $ 7,731, Medicare stand-alone PDP: $ 3,137, Total Medicare: $ 98,887, Commercial fully-insured: $ 501, Specialty benefits: $ 955, Medicare Supplement: $ 846, State-based contracts and other: $ 10,915, Total premiums: $ 112,104, Home solutions: $ 1,313, Pharmacy solutions: $ 904, Primary care: $ 1,248, Total external services revenue: $ 3,465 | Individual Medicare Advantage: $ 78,837, Group Medicare Advantage: $ 6,869, Medicare stand-alone PDP: $ 2,189, Total Medicare: $ 87,895, Commercial fully-insured: $ 3,527, Specialty benefits: $ 1,007, Medicare Supplement: $ 735, State-based contracts and other: $ 8,108, Total premiums: $ 101,272, Home solutions: $ 1,342, Pharmacy solutions: $ 849, Primary care: $ 842, Total external services revenue: $ 3,033 | N/A |
| Revenue by Geographic Region | N/A | N/A | N/A |


# Section 3: Business Analysis

## S3.1: Profitability Analysis

| Field | Answer |
| :---- | :---- |
| Revenue & Direct-Cost Dynamics | Revenue growth from 2022 to 2023 was 14.3%, increasing from $92,870 to $106,374. However, growth from 2023 to 2024 accelerated to 10.7%, reaching $117,761. The gross margin has shown a declining trend, decreasing from 18.50% in 2022 to 16.90% in 2023, and further down to 14.52% in 2024, indicating rising costs relative to revenue. The revenue breakdown for 2024 shows a significant contribution from Individual Medicare Advantage at $88,019, which reflects a growth from $78,837 in 2023. Total Medicare revenue increased from $87,895 in 2023 to $98,887 in 2024, indicating a strong performance in this segment. The geographic revenue distribution data is not available for analysis. |
| Operating Efficiency | Operating margin has declined from 4.09% in 2022 to 3.77% in 2023, and further to 2.18% in 2024, suggesting a deterioration in operating efficiency. Operating income decreased from $3,800 in 2022 to $4,013 in 2023, and then to $2,562 in 2024, indicating a negative trend in profitability despite revenue growth. The increase in operating expenses from $89,070 in 2022 to $115,199 in 2024, outpacing revenue growth, highlights challenges in cost management. |
| External & One-Off Impact | The effective tax rate increased from 21.36% in 2022 to 24.71% in 2023, and slightly decreased to 24.00% in 2024. This increase in the tax rate has negatively impacted net profit margins, which fell from 3.02% in 2022 to 1.03% in 2024. There are no specific non-recurring items or unusual patterns mentioned in the data, but the overall external economic factors may be influencing profitability, particularly in the healthcare sector. |


## S3.2: Financial Performance Summary

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Comprehensive financial health | In 2024, the company's total assets decreased to $46,479 million from $47,065 million in 2023, indicating a slight contraction in asset base. Current assets remained stable at $29,815 million, while non-current assets decreased to $16,664 million. Total liabilities also decreased to $30,034 million from $30,747 million, reflecting improved liability management. Shareholders' equity increased to $16,375 million, indicating a strengthening equity position despite the decline in total assets. The current ratio improved to 176.01%, suggesting enhanced liquidity and a strong capital structure. | In 2023, the company reported total assets of $47,065 million, an increase from $43,055 million in 2022, indicating positive asset growth. Current assets rose to $29,986 million, while non-current assets slightly increased to $17,079 million. Total liabilities also increased to $30,747 million from $27,685 million, indicating a rise in leverage. Shareholders' equity improved to $16,262 million, reflecting a solid equity position. The current ratio was 158.89%, indicating good liquidity and a stable capital structure. |
| Profitability and earnings quality | In 2024, revenue grew to $117,761 million, up from $106,374 million in 2023, indicating a revenue growth rate of approximately 13.0%. However, operating income decreased to $2,562 million from $4,013 million, leading to a decline in operating margin to 2.18% from 3.77%. Net profit also fell to $1,214 million, resulting in a net profit margin of 1.03%, down from 2.34% in 2023. Return on equity (ROE) decreased to 7.44% from 15.73%, indicating a decline in earnings quality and sustainability. | In 2023, the company achieved revenue of $106,374 million, a significant increase from $92,870 million in 2022. Operating income rose to $4,013 million, with an operating margin of 3.77%, reflecting effective cost management. Net profit was $2,484 million, resulting in a net profit margin of 2.34%. The return on equity (ROE) was 15.73%, indicating strong profitability and earnings sustainability during the year. |
| Operational efficiency | In 2024, the operating margin decreased to 2.18%, down from 3.77% in 2023, indicating challenges in cost management. The asset turnover ratio improved to 251.78%, suggesting better asset utilization despite the decline in operating income. Net cash from operations decreased to $2,966 million from $3,981 million in 2023, indicating a decline in operational efficiency and working capital management. | In 2023, the operating margin was 3.77%, reflecting effective cost management strategies. The asset turnover ratio was 236.07%, indicating efficient use of assets to generate revenue. Net cash from operations was $3,981 million, demonstrating strong operational efficiency and effective working capital management. |
| Financial risk identification and early warning | In 2024, the debt to equity ratio improved slightly to 183.41% from 189.07% in 2023, indicating better debt management. The interest coverage ratio decreased to 388.18%, down from 814.00%, suggesting increased financial risk due to lower operating income. The current ratio of 176.01% indicates strong liquidity, while the effective tax rate increased to 24.00%, which could impact net profitability. | In 2023, the debt to equity ratio was 189.07%, indicating a relatively high level of leverage. The interest coverage ratio was 814.00%, suggesting strong ability to cover interest expenses. The current ratio of 158.89% indicated good liquidity, while the effective tax rate was 24.71%, which could pose a risk to net profitability if not managed effectively. |
| Future financial performance projection | Based on 2024 data, the company is expected to face challenges in maintaining profitability due to declining margins and increased operational costs. However, revenue growth indicates potential for market expansion. The cash flow from operations is under pressure, which may affect future investment activities and dividend policy. Strategic focus on cost management and operational efficiency will be critical for sustaining cash flow and supporting growth initiatives. | In 2023, the company demonstrated strong revenue growth and profitability, suggesting a positive outlook for future performance. The effective management of cash flow from operations and a stable dividend policy indicate sustainability. Continued investment in market expansion and business development will be essential to capitalize on growth opportunities and enhance overall financial performance. |


## S3.3: Business Competitiveness

| Field | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Business Model | Humana operates primarily through two segments: Insurance and CenterWell. The Insurance segment generates revenue through Medicare benefits, state-based contracts, and employer group commercial health insurance products. It includes individual Medicare Advantage plans, group Medicare Advantage plans, and Medicare stand-alone prescription drug plans (PDP). The CenterWell segment focuses on pharmacy solutions, primary care, and home solutions, enhancing healthcare experiences and potentially lowering costs. Revenue is derived from premiums, administrative services, and value-based arrangements, with a significant portion (85%) coming from government contracts. | Humana operates primarily through two segments: Insurance and CenterWell. The Insurance segment generates revenue through Medicare benefits, employer group commercial fully-insured medical and specialty health insurance, and administrative services only (ASO). It includes products marketed to individuals and employer groups, such as dental, vision, and other supplemental health benefits. The CenterWell segment focuses on payor-agnostic healthcare services, including pharmacy solutions, primary care, and home solutions. Revenue is derived from monthly premiums from government contracts and employer groups, as well as fees for services rendered. |
| Market Position | Humana holds a strong position in the Medicare market, with approximately 16 million members across its medical benefit plans. It is a market leader in Medicare Advantage, with 75.6% of its premiums coming from individual Medicare Advantage contracts. However, it faces intense competition from larger managed care companies and national insurance firms. The company has experienced a decline in its star ratings, with only 25% of its Medicare Advantage members enrolled in plans rated 4 stars or higher for 2025, down from 94% in 2024, which may impact its competitive standing and revenue from quality bonuses. | Humana holds a significant market position in the health benefits industry, with approximately 17 million members in medical benefit plans and 5 million in specialty products. The company is a market leader in Medicare Advantage, with 74.9% of its total premiums and services revenue coming from individual Medicare Advantage contracts. Humana's competitive position is challenged by larger competitors with greater financial resources, but it maintains a strong presence in the Medicare market, serving approximately 8.8 million Medicare members. The company is recognized for its integrated care delivery model, which enhances member engagement and health outcomes. |


# Section 4: Risk Factors

## S4.1: Risk Factors

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Market Risks | The health benefits industry is highly competitive, with competitors having larger membership bases and greater financial resources. This competition may affect our ability to sell products and retain customers, particularly in light of market conditions and customer behavior. | The health benefits industry is highly competitive, with competitors having larger membership bases and greater financial resources. Market conditions, including changes in interest rates, can significantly impact investment income and the value of the investment portfolio, which is primarily composed of fixed maturity securities. |
| Operational Risks | Operational challenges include managing relationships with healthcare providers, which are critical for delivering services to members. Failure to maintain satisfactory relationships with providers could lead to higher healthcare costs and impact service delivery. | Operational challenges include managing healthcare costs, ensuring compliance with clinical initiatives, and maintaining relationships with healthcare providers. The company faces risks related to the management of its pharmacy business, including regulatory compliance and supply chain disruptions. |
| Financial Risks | Volatility in securities and credit markets, including changes in interest rates, may adversely affect the value of our investment portfolio. We have entered into interest-rate swap agreements to manage this risk, but there remains a risk of declines in fair value and material realized losses. | Financial risks include exposure to interest rate fluctuations affecting investment income and the value of the investment portfolio. The company has entered into interest rate swap agreements to manage this risk, and ongoing evaluations of investment securities for impairment are conducted quarterly. |
| Compliance Risks | We are subject to extensive government regulations, including those related to Medicare and Medicaid programs. Changes in these regulations, as well as ongoing audits and investigations, could result in significant penalties or operational changes that adversely affect our financial position. | The company is subject to extensive government regulations, including the Health Care Reform Law and various state laws affecting its operations. Compliance with laws such as HIPAA and the False Claims Act is critical, and any violations could result in significant penalties or operational changes. |


# Section 5: Corporate Governance

## S5.1: Board Composition
| Name | Position | Total Income |
| :---- | :---- | -----------: |
| James A. Rechtin | President and Chief Executive Officer, Director | N/A |
| Kurt J. Hilzinger | Chairman of the Board | N/A |
| Raquel C. Bono, M.D. | Director | N/A |
| Frank A. D'Amelio | Director | N/A |
| David T. Feinberg, M.D. | Director | N/A |
| Wayne A. I. Frederick, M.D. | Director | N/A |
| John W. Garratt | Director | N/A |
| Karen W. Katz | Director | N/A |
| Macy S. Klevorn | Director | N/A |
| Jorge S. Mesquita | Director | N/A |
| Brad D. Smith | Director | N/A |
| Gordon Smith | Director | N/A |

## S5.2: Internal Controls
| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Risk assessment procedures | We assessed the effectiveness of the Company's internal control over financial reporting as of December 31, 2024. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013). | We assessed the effectiveness of the Company's internal control over financial reporting as of December 31, 2023, using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013). |
| Control activities | Our control environment is the foundation for our system of internal control over financial reporting and is embodied in our Code of Ethics and Business Conduct, which we currently refer to as the Humana Inc. Ethics Every Day. It sets the tone of our organization and includes factors such as integrity and ethical values. Our internal control over financial reporting is supported by formal policies and procedures which are reviewed, modified and improved as changes occur in business conditions and operations. | Our control environment is the foundation for our system of internal control over financial reporting and is embodied in our Code of Ethics and Business Conduct, which we currently refer to as the Humana Inc. Ethics Every Day. It sets the tone of our organization and includes factors such as integrity and ethical values. Our internal control over financial reporting is supported by formal policies and procedures which are reviewed, modified and improved as changes occur in business conditions and operations. |
| Monitoring mechanisms | The Audit Committee of the Board of Directors, which is composed solely of independent outside directors, meets periodically with members of management, the internal auditors and our independent registered public accounting firm to review and discuss internal controls over financial reporting and accounting and financial reporting matters. Our independent registered public accounting firm and internal auditors report to the Audit Committee and accordingly have full and free access to the Audit Committee at any time. | The Audit Committee of the Board of Directors, which is composed solely of independent outside directors, meets periodically with members of management, the internal auditors and our independent registered public accounting firm to review and discuss internal controls over financial reporting and accounting and financial reporting matters. |
| Identified material weaknesses or deficiencies | N/A | N/A |
| Effectiveness | Based on our assessment, we determined that, as of December 31, 2024, the Company's internal control over financial reporting was effective based on those criteria. | Based on our assessment, we determined that, as of December 31, 2023, the Company's internal control over financial reporting was effective based on those criteria. |


# Section 6: Future Outlook

## S6.1: Strategic Direction

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Mergers and Acquisition | In 2024, Humana engaged in discussions regarding potential investments, acquisitions, and divestitures to further its business objectives. The company has a strategic partnership with Welsh, Carson, Anderson & Stowe (WCAS) to develop primary care centers, with the option to purchase additional clinics for approximately $600 million to $700 million in 2025, and up to $2.5 billion to $3.5 billion for future cohorts from 2025 to 2032, depending on various factors. | In 2023, Humana engaged in discussions regarding possible investments, acquisitions, and divestitures to further business objectives. The company has a strategic partnership with Welsh, Carson, Anderson & Stowe (WCAS) to develop additional primary care centers, with the option to purchase the first cohort of clinics in 2025 for approximately $550 million to $650 million. Additionally, the company may acquire WCAS's interest in the partnership over the next 2 to 9 years, which could require $2.0 billion to $3.0 billion based on current projections. |
| New technologies | Humana is focused on enhancing its integrated care delivery model, which includes leveraging technology to improve member engagement and streamline operations. The company is investing in systems powered by artificial intelligence and machine learning to enhance service delivery and operational efficiencies. | Humana is focused on enhancing its integrated care delivery model, which includes investments in technology to improve member engagement and care coordination. The company operates primary care clinics under the Primary Care Organization (PCO) and has established a Medical Services Organization (MSO) to support value-based care. The strategic partnership with WCAS aims to expand primary care capabilities, which is integral to their technology and service delivery enhancements. |
| Organisational Restructuring | Humana is committed to talent development and has implemented various initiatives to promote continuous learning and career advancement for its employees. The company has a comprehensive range of resources for professional development, including education and certification program assistance. Additionally, the company is actively managing succession and retention of key executives to ensure organizational stability. | In February 2023, Humana announced its planned exit from the Employer Group Commercial Medical Products business, indicating a strategic realignment to focus on more sustainable offerings. The company is committed to talent development through various programs, including the Humana Learning Center and mentoring initiatives, aimed at upskilling and reskilling associates. Additionally, the company has implemented workforce optimization measures, resulting in severance charges of $199 million in 2023. |


## S6.2: Challenges and Uncertainties

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Economic challenges such as inflation, recession risks, and shifting consumer behavior that could impact revenue and profitability. | The company faces significant economic challenges due to ongoing volatility in the securities and credit markets, including changes in interest rates that may adversely affect the value of its investment portfolio and the investment income derived from it. The current economic environment poses uncertainties regarding the availability of credit, which could impact the company's ability to finance operations and growth. Additionally, the company is exposed to risks related to medical cost inflation, increased healthcare service utilization, and regulatory changes that may affect profitability and operational costs. | The company faces significant economic challenges due to ongoing volatility in the securities and credit markets, including changes in interest rates that may adversely affect the value of its investment portfolio and the investment income derived from it. The company is also exposed to risks related to the availability of credit, which may be impacted by market conditions and perceptions of its financial prospects. Additionally, the company must manage costs associated with healthcare services, which are sensitive to medical cost inflation, increased utilization of services, and regulatory changes that may affect premium payments and operational costs. |
| Competitive pressures from both established industry players and new, disruptive market entrants that the company faces. | The company operates in a highly competitive health benefits industry, facing pressures from both established players and new entrants. Competitors may have larger membership bases and greater financial resources, which can influence the company's ability to attract and retain customers. The competitive landscape is further complicated by the need to manage premium pricing amidst rising medical and administrative costs. Additionally, the company must navigate the complexities of maintaining relationships with healthcare providers, which are critical for delivering services and managing costs effectively. | The company operates in a highly competitive health benefits industry, facing pressures from both established players and new entrants. Competitors may have larger membership bases and greater financial resources, which can influence the company's ability to sell products and retain customers. The company also faces intense competition to contain premium prices while managing increasing medical and administrative costs. Furthermore, the company must navigate regulatory changes that could impact its profitability and market position, particularly in the Medicare Advantage and Prescription Drug Plan sectors. |


## S6.3: Innovation and Development Plans

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| R&D investments, with a focus on advancing technology, improving products, and creating new solutions to cater to market trends | N/A | N/A |
| New product launches, emphasizing the company's commitment to continuously introducing differentiated products | N/A | N/A |
